UB Paderborn / Katalog / Suche / in CDI

Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation

Molecular pharmacology, 2012-12, Vol.82 (6), p.1008-1021

2012

Volltextzugriff (PDF)

The Perspective of DMPK on Recombinant Adeno-Associated Virus-Based Gene Therapy: Past Learning, Current Support, and Future Contribution

The AAPS journal, 2022-01, Vol.24 (1), p.31-31, Article 31

2022

Volltextzugriff (PDF)

Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS

Pharmaceutical research, 2016-09, Vol.33 (9), p.2280-2288

2016

Volltextzugriff (PDF)

Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

Clinical pharmacology and therapeutics, 2018-11, Vol.104 (5), p.890-899

2018

Volltextzugriff (PDF)

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

Clinical pharmacokinetics, 2019-04, Vol.58 (4), p.431-449

2019

Volltextzugriff (PDF)

In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties

Toxicological sciences, 2017-06, Vol.157 (2), p.487-499

2017

Volltextzugriff (PDF)

Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development

Acta pharmaceutica Sinica. B, 2022-06, Vol.12 (6), p.2751-2777

2022

Volltextzugriff (PDF)

Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice

Journal of pharmacokinetics and pharmacodynamics, 2022-10, Vol.49 (5), p.525-538

2022

Volltextzugriff (PDF)

Predicting Approximate Clinically Effective Doses in Oncology Using Preclinical Efficacy and Body Surface Area Conversion: A Retrospective Analysis

Frontiers in pharmacology, 2022-04, Vol.13, p.830972-830972

2022

Volltextzugriff (PDF)

A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys

The Journal of pharmacology and experimental therapeutics, 2019-08, Vol.370 (2), p.182

2019

Volltextzugriff (PDF)

Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans

Xenobiotica, 2019-07, Vol.49 (7), p.852-862

2019

Volltextzugriff (PDF)

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria

Drug metabolism and disposition, 2013-07, Vol.41 (7), p.1347

2013

Volltextzugriff (PDF)

Evaluation of drug-transporter interactions using in vitro and in vivo models

Current drug metabolism, 2007-05, Vol.8 (4), p.341

2007

Volltextzugriff (PDF)

PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper

The AAPS journal, 2023-07, Vol.25 (5), p.78-78, Article 78

2023

Volltextzugriff (PDF)

Sinusoidal Organic Anion-Transporting Polypeptide 1B1/1B3 and Bile Canalicular Multidrug Resistance-Associated Protein 2 Play an Essential Role in the Hepatobiliary Disposition of a Synthetic Cyclic Dinucleotide (STING Agonist)

The AAPS journal, 2022-09, Vol.24 (6), p.99, Article 99

2022

Volltextzugriff (PDF)

Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP)

Xenobiotica, 2018-05, Vol.48 (5), p.467-477

2018

Volltextzugriff (PDF)

Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts

Molecular cancer therapeutics, 2020-10, Vol.19 (10), p.2079-2088

2020

Volltextzugriff (PDF)

Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling

The AAPS journal, 2016-11, Vol.18 (6), p.1512-1523

2016

Volltextzugriff (PDF)

Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes

Drug metabolism and disposition, 2006-09, Vol.34 (9), p.1600

2006

Volltextzugriff (PDF)

Prediction of Hepatic Efflux Transporter-Mediated Drug Interactions: When Is it Optimal to Measure Intracellular Unbound Fraction of Inhibitors?

Journal of pharmaceutical sciences, 2017-09, Vol.106 (9), p.2401-2406

2017

Volltextzugriff (PDF)

Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles

Xenobiotica, 2018-11, Vol.48 (11), p.1173-1183

2018

Volltextzugriff (PDF)

Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells

Drug metabolism and disposition, 2005-05, Vol.33 (5), p.637

2005

Volltextzugriff (PDF)

Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles

Bioorganic & medicinal chemistry letters, 2016-01, Vol.26 (2), p.551-555

2016

Volltextzugriff (PDF)

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism

PloS one, 2015-12, Vol.10 (12), p.e0144825-e0144825

2015

Volltextzugriff (PDF)

Interactions of cyclosporin a with breast cancer resistance protein

Drug metabolism and disposition, 2007-04, Vol.35 (4), p.576

2007

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation

The Perspective of DMPK on Recombinant Adeno-Associated Virus-Based Gene Therapy: Past Learning, Current Support, and Future Contribution

Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS

Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties

Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development

Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice

Predicting Approximate Clinically Effective Doses in Oncology Using Preclinical Efficacy and Body Surface Area Conversion: A Retrospective Analysis

A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys

Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria

Evaluation of drug-transporter interactions using in vitro and in vivo models

PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper

Sinusoidal Organic Anion-Transporting Polypeptide 1B1/1B3 and Bile Canalicular Multidrug Resistance-Associated Protein 2 Play an Essential Role in the Hepatobiliary Disposition of a Synthetic Cyclic Dinucleotide (STING Agonist)

Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP)

Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts

Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling

Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes

Prediction of Hepatic Efflux Transporter-Mediated Drug Interactions: When Is it Optimal to Measure Intracellular Unbound Fraction of Inhibitors?

Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles

Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells

Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles

KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism

Interactions of cyclosporin a with breast cancer resistance protein

Suchergebnisse filtern